Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for m...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krishna Vishwa Vidyapeeth (Deemed to be University), Karad
2015-01-01
|
| Series: | Journal of Krishna Institute of Medical Sciences University |
| Subjects: | |
| Online Access: | http://jkimsu.com/jkimsu-vol4no1/JKIMSU,%20Vol.%204,%20No.%201,%20Jan-Mar%202015%20Page%2070-76.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Iron overload is a predictable and lifethreatening
complication in patients with thalassemia.
Effective and convenient iron chelation remains one of
the main targets of clinical management of thalassemia
major. The development of a safe and effective chelator
has been the goal for many years. Aims and Objective:
It was aimed to compare the effect of deferiprone,
deferoxamine and combination of deferiprone and
deferoxamine on serum ferritin value in betathalassemia
patients. Material and Methods: This
controlled clinical trial was conducted on 46 major
beta-thalassemic patients. Fifteen patients in
deferiprone group received deferiprone 75mg/kg/day
three times a day orally. Nineteen patients in
deferoxamine group received deferoxamine 30-50
mg/kg/day subcutaneously for 8-12 hours/day and 5
days per week. Twelve patients in combined therapy
group received deferiprone 75 mg/kg/day three times a
day orally with deferoxamine 30–50 mg/kg subcutaneously
every other day. Serum ferritin value was
th th measured at the beginning and at the end of 6 and 12
months of study. Results: The mean of serum ferritin
value in deferiprone group insignificantly increased
from 2731± 1398.5 µg/L at the beginning to 2788.5 ±
th 978.6 µg/L and to 3331.8 ± 1833.9 µg/L at the end of 6
th and 12 months of study, respectively. The mean of
serum ferritin value in deferoxamine group insignificantly
increased from 2883.5 ± 1598.1 µg/L at the
th beginning to 2935.3 ± 1258.2 µg/L at the end of 6
month of study and decreased to 2773.8 ± 1216.1 µg/L
th and 12 month of study. The mean of serum ferritin
level in combined therapy group significantly
decreased from 7498.7 ± 3512.9 µg/L at the beginning
to 4839.9 ± 2698.2 µg/L (P < 0.001) and to 4298.2 ±
th th 2288.7 µg/L (P < 0.001) at the end of 6 and 12 months of study, respectively. Conclusion: Combined therapy
significantly decreases serum ferritin level. Study
suggests deferiprone as a significant addition to
support therapy in patients with betathalassemia major
on regular transfusion regimens. |
|---|---|
| ISSN: | 2231-4261 2231-4261 |